Patrick Moley

Alexander Blostein

Alex Kramm

Benjamin Budish

Kyle Voigt

Carlos Gomez-Lopez

Dan Fannon

Ben Budish

Carlos Gomes-Lopez

Christopher Allen

Daniel Fannon

William Katz

- Faruqi & Faruqi, LLP is investigating **Marex Group plc** (NASDAQ: MRX) for alleged federal securities law violations, with a **December 8, 2025 deadline** for investors to seek lead plaintiff status in a class action lawsuit.  **[1997464_20251028NY08030:0]** 
- The complaint alleges Marex made false and/or misleading statements, including selling over-the-counter financial instruments to itself and having inconsistencies in its financial statements, rendering them unreliable.  **[1997464_20251028NY08030:0]** 
- On **August 5, 2025**, NINGI Research released a report accusing Marex of a multi-year accounting scheme involving off-balance-sheet entities, fictitious transactions, and misleading disclosures to hide losses and inflate profits, including concealing nearly **$1 billion** in derivatives exposure.  **[1997464_20251028NY08030:0]** 
- Following the report, Marex's stock dropped **6.2%**, closing at **$35.31**.  **[1997464_20251028NY08030:0]** 
- The investigation covers securities purchased or acquired between **May 16, 2024 and August 5, 2025**.  **[1997464_20251028NY08030:0]**

Marex Group Faces Securities Class Action Investigation

- Faruqi & Faruqi, LLP is investigating **Marex Group plc** (NASDAQ: MRX) and a federal securities class action has been filed, with a **December 8, 2025**, deadline for investors to seek lead plaintiff status.  **[1997464_20251015NY97828:0]** 
- The class action covers investors who purchased Marex securities between **May 16, 2024, and August 5, 2025**.  **[1997464_20251015NY97828:0]** 
- The complaint alleges Marex made false or misleading statements and failed to disclose issues such as selling over-the-counter financial instruments to itself and inconsistencies in financial statements, leading to unreliable financial reporting.  **[1997464_20251015NY97828:0]** 
- A NINGI Research report on **August 5, 2025**, accused Marex of a multi-year accounting scheme, citing a **$17 million fabricated receivable** and concealed **nearly $1 billion in derivatives exposure**.  **[1997464_20251015NY97828:0]** 
- Following the report, Marex's stock dropped **6.2%**, closing at **$35.31** on August 5, 2025.  **[1997464_20251015NY97828:0]**

- On **October 10, 2025**, CEO **Ian Lowitt** acquired **32,465 ordinary shares**, increasing his total holding to **2,615,016 ordinary shares**.  **[1997464_0001193125-25-239659_d920594dex991.htm:0]** 
- On **October 13, 2025**, Paolo Tonucci, Chief Strategist and CEO of Capital Markets, purchased **30,000 ordinary shares**, bringing his total holding to **1,108,342 ordinary shares**.  **[1997464_0001193125-25-239659_d920594dex991.htm:0]** 
- On **October 14, 2025**, former Marex Board members Sir Jeremy Isaacs and Roger Nagioff each acquired **35,000 ordinary shares**.  **[1997464_0001193125-25-239659_d920594dex991.htm:0]** 
- These purchases follow earlier acquisitions in **August** by Non-Executive Chairman **Robert Pickering** (**2,700 ordinary shares**) and Board member **Konstantin Graf von Schweinitz** (**7,100 ordinary shares**).  **[1997464_0001193125-25-239659_d920594dex991.htm:0]** 
- CEO Ian Lowitt stated that these acquisitions underscore the executive leadership team's **strong belief in Marex's growth trajectory and future potential**, with the team collectively owning **more than 7%** of the company.  **[1997464_0001193125-25-239659_d920594dex991.htm:0]**

Marex Group plc Announces Share Purchases by Directors and Officers

- Marex Group plc announced that its **Chief Executive Officer, Ian Lowitt**, purchased **32,465 ordinary shares** in the open market on **October 10**.  **[1997464_0001193125-25-238153_d81338dex991.htm:0]** 
- Following this purchase, Ian Lowitt's total holding in Marex Group plc is **2,615,016 ordinary shares**.  **[1997464_0001193125-25-238153_d81338dex991.htm:0]** 
- This announcement was made via a press release on **October 13, 2025**, and subsequently filed as a Form 6-K on **October 14, 2025**.  **[1997464_0001193125-25-238153_d81338d6k.htm:0]** **[1997464_0001193125-25-238153_d81338dex991.htm:0]**

Marex announces CEO share purchase

- **Berger Montague PC** has announced a class action lawsuit against **Marex Group plc (NASDAQ: MRX)** on behalf of investors who purchased shares during the **Class Period of May 16, 2024, through August 5, 2025**.  **[1997464_20251013DC95871:0]** 
- The lawsuit alleges that Marex engaged in a **multi-year accounting scheme** involving opaque off-balance-sheet entities, fictitious intercompany transactions, and misleading disclosures to conceal significant losses, inflate profits, and mask true risk exposure.  **[1997464_20251013DC95871:0]** 
- Specific allegations include a **fabricated $17 million receivable**, a subsidiary with profits inflated by **150%** before liquidation, an asset valued at **$14.9 million** sold for **$2.5 million**, and nearly **$1 billion** in concealed off-balance-sheet derivatives exposure.  **[1997464_20251013DC95871:0]** 
- Following a report detailing these allegations on August 5, 2025, Marex's stock price fell **$2.33**, or **6.2%**, closing at **$35.31**.  **[1997464_20251013DC95871:0]** 
- Investors who purchased Marex securities during the Class Period have until **December 8, 2025**, to seek appointment as a lead plaintiff representative.  **[1997464_20251013DC95871:0]**

Marex Group Faces Class Action Lawsuit Over Alleged Accounting Scheme

- Marex Group plc reported strong preliminary Q3 2025 results, with **revenues expected between $475 million and $485 million** and **Adjusted Profit Before Tax between $96 million and $101 million**, representing year-over-year increases of **23% and 22% at the midpoint**, respectively.  **[1997464_0001193125-25-234069_d13982dex991.htm:0]** 
- The company achieved an **Adjusted Return on Equity of approximately 27%** and an **Adjusted Profit Before Tax Margin of around 21%** for Q3 2025.  **[1997464_0001193125-25-234069_d13982dex991.htm:0]** 
- **Average Clearing Client balances grew 4%** to **$13.3 billion** in Q3 2025, with US client assets reaching a record of over **$10 billion in October**.  **[1997464_0001193125-25-234069_d13982dex991.htm:0]** 
- This performance was achieved in a **more challenging operating environment**, as exchange volumes at CME and ICE were down over 15% on average in Q3 compared to Q2.  **[1997464_0001193125-25-234069_d13982dex991.htm:0]**

Marex Group (MRX)